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Abstract 
A novel thin layer chromatographic procedure was devised to evaluate the activity of rhodamine-B tagged peptide hormone such 
as vasopressin & octreotide. Peptide hormones viz. octreotide and vasopressin were added with rhodamine-B (0.2 ml of 
concentration 2.5mg/ml) and were estimated through thin layer chromatography (TLC) in a concentration and time dependent 
manner i.e. 25μg, 50μg for 30 & 60 minutes and 4.8μg, 9.6μg for 30 & 60 minutes respectively. The solvent medium used was a 
mixture of butanol, acetic acid and water in a ratio of 4:1:1. Stationary phase used in this experiment was Silica gel mixed with an 
inert binder like calcium sulphate and water. Different peptides travel at different rates due to the differences in their at traction to 
the stationary phase and because of difference in solubility in the solvent. The plates were made to visualize under a UV 
detector and respective Rf values were calculated. Results showed that rhodamine-B tagged peptides were well seen under UV 
detector as well as with naked eyes and is an efficacious marker when compared with other developing systems such as 
ninhydrin, iodine spray etc. 
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Introduction 
G protein coupled receptors (GPCR) binding ligands 
are extensively studied as GPCRs represent the single 
largest molecular target of therapeutic drugs currently on 
the market, but is also the most common target in high-
throughput screening (HTS) assays for identifying 
potential new drug candidates 1. We chose two candidate 
hormones i.e vasopressin (9 amino acid) and Octreotide 
(8 aminoacid) almost similar in size for this study. Both 
these hormones bind to their respective GPCR and their 
analogues are being studied for novel therapeutic 
purposes. Vasopressin is a human hormone that is 
released when the body is low on water; it causes the 
kidneys to conserve water, but not salt, by concentrating 
the urine and reducing urine volume. It also raises blood 
pressure by inducing moderate vasoconstriction. 
Vasopressin is a peptide hormone. It is derived from a 
preprohormone precursor that is synthesized in the 
hypothalamus, from which it is liberated during transport 
to the posterior pituitary. Most of it is stored in the 
posterior part of the pituitary gland to be released into the 
blood stream; some of it is also released directly into the 
brain.The vasopressins are peptides consisting of nine 
amino acids (nonapeptides) 2. The amino acid sequence 
of arginine vasopressin is Cys-Tyr-Phe-Gln-Asn-Cys-Pro-
Arg-Gly, with the cysteine residues forming a sulfur bridge. 
The structure of oxytocin another posterior pituitary 
hormone is very similar to that of the vasopressins: it is 
also a nonapeptide with a sulfur bridge and its amino acid 
sequence differs at only two positions. On the other hand, 
Octreotide is the acetate salt of a cyclic octapeptide. It is 
a long acting octapeptide with pharmacologic properties 
mimicking those of the natural hormone somatostatin 
3.Octreotide is known chemically as L-Cysteinamide, D-
phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-
lysyl-L-threonyl-N- [2-hydroxy-1-(hydroxylmethyl) propyl], 
cyclic(2→7)disulfide;[R-(R*,R*)].It is commercially 
available  as Sandostatin LAR® Depot (octreotide acetate 
for injectable suspension) and is available in a vial 
containing the sterile drug product, which when mixed 
with diluent, becomes a suspension that is given as a 
monthly intragluteal injection. 
The octreotide is uniformly distributed within the 
microspheres which are made of a biodegradable 
glucose star polymer, D,L-lactic and glycolic acids 
copolymer. Sterile mannitol is added to the microspheres 
to improve suspendibility. Somatostatin is a 14 amino 
acid hormone. Octreotide is a derivative of somatostatin 
with a much longer half life. Both have the same 
therapeutic properties. The molecular weight of octreotide 
is 1019 daltons. It is used for the treatment of 
oesophageal varices. Most of the HTS procedures are 
still presently based on radioligand binding competition 
assays. Fluorescence approaches, based on the 
development of fluorescent ligands, offer a 
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nonradioactive alternative to radioligand binding assays. 
In this study, we utilized the fluorescent dye rhodamine B 
and tagged it to vasopressin and octreotide for thin layer 
chromatography evaluation and determination of 
retention factor (Rf) values4. 
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Materials & Methods: 
Chemicals and drugs used: Octreotide (United 
biotech Ltd, India), Arginine vasopressin ( SG Pharma 
Private Ltd, India), Rhodamine B (Sigma Ltd ,India,), 
Butanol (Qualigens, India), Acetic acid (Qualigens, India), 
Silica gel (ACME Chemicals, India). 
TLC equipment: All the equipments used for TLC 
used were from ACME synthetics, Mumbai, India. 
Acme applicator was used for thin layer 
chromatography, beakers, capillary pipettes for 
spotting solutions, rulers, hot plates (used in the hood), 
and gloves were used for all chemical handling 
procedures. 
Protocol of drug and chemical usage:    
Peptides: Vasopressin (4.8μg, 9.6μg), Octreotide 
(25μg, 50μg). 
Rhodamine dye was used in a concentration 
2.5mg/ml of water. 
Solvent for TLC (4:1:1 of Butanol, acetic acid & 
water). 
TLC plates (approximately 2” x 3”). 
 
 
Procedure used for thin layer chromatography: 
Chromatography is used to separate mixtures of 
substances into their components. All forms of 
chromatography work on the same principle. They all 
have a stationary phase (a solid or a liquid supported on 
a solid) and a mobile phase (a liquid or a gas)5. The 
mobile phase flows through the stationary phase and 
carries the components of the mixture with it. Different 
components travel at different rate. The movement of the 
analyte is expressed by its retention factor (Rf) such that  
 
Rf =      Distance moved by solute from origin 
             Distance travelled by solvent from origin 
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Thin layer preparation: 
A slurry of silica gel (stationary phase) generally in 
water is applied to a glass, generally 20 cm square, as a 
uniform thin layer by means of a plate spreader starting at 
one end of the plate & moving progressively to the other. 
The thickness of the slurry layer is of the order of 0.25mm 
thick. Once the slurry layer has been prepared, the plates 
are dried out in an oven at 100-120°C to leave the 
coating of stationary phase.  
Sample application:    
The sample is applied to the plate 2.0cm from the 
edge by means of capillary pipette. The sample used was 
octreotide & vasopressin mixed with rhodamine in two 
different concentrations i.e. 
(i)  (A) 0.5 ml octreotide (concentration= 25μg) + 0.2 ml 
rhodamine (concentration=2.5mg/ml)       
(B) 1.0 ml octreotide (concentration=50μg) + 0.2ml 
rhodamine (concentration=2.5mg/ml) 
(ii)  (A) 0.2ml vasopressin (concentration=4.8μg) + 0.2ml 
rhodamine (concentration=2.5mg/ml) 
       (B)  0.4ml vasopressin (concentration=9.6μg) + 0.2ml 
rhodamine (concentration=2.5mg/ml) 
        A small spot of the sample was applied on the plate. 
 
Plate development:  
Separation most commonly takes place in a glass 
tank that contains the developing solvent (mobile phase) 
to a depth of about 1.5cm. The solvent system used was 
butanol, acetic acid and water in the ratio of 4:1:1. This 
was allowed o stand for at least 1hr with a lid over the top 
of the tank to ensure that the atmosphere within the tank 
becomes saturated with solvent vapour (equilibration). 
Unless this is done, irregular running of the solvent will 
occur as it ascends the plate by capillary action, resulting 
in poor separations being achieved. After equilibration, 
the lid is removed & the thin layer plate with sample is 
then placed vertically in the tank so that it stands in the 
solvent.  The lid is replaced & separation of the 
compounds occurs as the solvent travels up the plate. 
One of the biggest advantages of TLC is the speed at 
which separation is achieved. This is commonly about 
30mins & hardly ever greater than 90mins. The plate is 
then removed from the tank & allowed to dry. 
Analyte detection:  
There are several detection methods. The plate is 
taken after 30mins and kept in the solvent system and 
examined under UV detector i.e. under UV light which 
shows the position of UV absorbing or fluorescent 
compounds. Then again the plate is examined after 
60mins under UV detector and Rf values were calculated. 
Results 
Table 1 depicts the concentration, time duration and Rf value calculations for rhodamine tagged vasopressin 
evaluated by TLC. 
 
 
     S. no.  
 
 Concentration 
        (μg) 
 
Time Duration 
      (mins) 
 
Distance 
travelled         by 
solute(cms) 
 
Distance travelled           
by solvent(cms)     
 
Rf value 
       1.         4.8         30        6.0         6.5   0.923 
       2.         9.6         30        5.5         6.0   0.916 
       3.         4.8         60        8.0         9.0   0.888 
       4.         9.6         60        8.4         9.5   0.884 
       
                                                                     
Table 2 depicts the concentration, time duration and Rf value calculations for rhodamine B tagged octreotide 
evaluated by TLC.  
 
 
      S.no 
 
Concentration 
        (μg) 
 
Time Duration 
       (mins) 
 
Distance 
travelled           by 
solute(cms) 
 
Distance travelled            
by solvent(cms) 
 
Rf value 
        1.          25          30         5.9          6.3     0.936 
        2.          50          30         6.0          6.7     0.895 
        3.          25          60         8.6        10.4     0.826 
        4.          50          60         8.6          9.8     0.877 
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Figure 1 shows the silica gel coated plates spotted with rhodamine B tagged vasopressin (4.8 μg and 9.6 μg) for chromatographic evaluation 
for a duration of 30 minutes. Figure 2 shows the silica gel plates spotted with rhodamine B tagged vasopressin (4.8μg and 9.6 μg) used for 
chromatographic evaluation for duration of 60 minutes. Figure 3 shows the silica gel coated plates spotted with rhodamine B tagged 
octreotide (25 μg and 50 μg) used for chromatographic evaluation for a duration of 30 minutes. Figure 4 shows the silica gel coated plates 
spotted with rhodamine B tagged octreotide (25 μg and 50 μg) used for chromatographic evaluation for a duration of 60 minutes. 
 
Discussion 
 
Thin layer chromatography has extensive 
application in protein chemistry. This includes recovery 
of peptides in microgram and nanogram quantities for 
further primary structural identification of peptides, 
peptides mapping and determination of molecular 
weights of peptides & proteins 6. The various peptides 
and proteins have been located on thin layer 
chromatography by using ninhydrin, fluorescamin, 
iodine vapors or UV light. In our study we used 
rhodamine B as fluorescent material and evaluated the 
retention factor (Rf) of vasopressin and octreotide as 
shown in Table 1 & 2 and also depicted in Figures 1 to 
4. Our results clearly show a very good binding and 
because of the increased sensitivity of the fluorescence 
readers and of the brightness of the fluorophores, most 
of these studies can be performed using fluorescence-
based technologies. Fluorescent ligands selective for a 
given receptor family or a given receptor subtype are 
consequently very useful labeling and pharmacological 
tools. These ligands i.e vasopressin were defined as 
useful for the study of renal AVP receptors by 
fluorescence microscopy, particularly the fluorescein 
and rhodamine-labeled agonists. Whereas fluorescein 
exhibits low photostability, which restricts its use for 
imaging events occurring over long time periods, and 
therefore rhodamine fluorophore is ideal in that it 
possesses a high molar extinction coefficient and does 
not photobleach readily. The synthesis and 
characterization of first generations of fluorescent 
agonists and antagonists for AVP/OT receptors led to 
the discovery of very promising pharmacological tools 
but their use was limited to fluorescence microscopy 
techniques applied to the investigation of the cellular 
expression and localization of receptors. In this study 
we used optimum concentration of vasopressin and we 
got good elution after 30 and 60 minutes period. In 
earlier studies it was shown that the sensitivity of the 
fluorophores attached to these ligands is far from being 
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equivalent to that of usual radioisotopes (3H, 125I), and 
ligand binding assays could not generally be 
developed7. Thus it is not surprising that a posterior 
derivatization of AVP/OT analogues with bulky 
fluorophores like fluorescein or rhodamine at this 
particular position (amino acid residue 8) led to the 
successful development of numerous fluorescent 
ligands retaining high affinity, selectivity, and functional 
activity for these receptors. This residue is finally not 
crucial for binding, although it has been demonstrated 
to be involved in receptor subtype binding selectivity8. 
The results obtained with octreotide also suggest that 
its chemical configuration assimilates well with 
rhodamine B as a flurophore. As indicated in the 
introduction, GPCRs represent the single largest 
molecular target of therapeutic drugs currently on the 
market, but are also the most common target in high-
throughput screening (HTS) assays for identifying 
potential new drug candidates. Most of these HTS 
procedures are still presently based on radioligand 
binding competition assays. Fluorescence approaches, 
based on the development of fluorescent ligands, offer 
a nonradioactive alternative to radioligand binding 
assays 9,10. Fluorescence polarization and FRET (such 
as homogenous-time resolved fluorescence (HTRF)) 
techniques are even more useful since they can be 
achieved without the separation of the bound and free 
ligand fractions, leading to the development of 
homogenous microplate format assays with cell 
membrane preparation or whole cell samples. The 
development of these techniques has stemmed first 
from the elaboration of numerous sensitive microplate 
readers, and second from the synthesis of new 
fluorescent probes. Among the new fluorophores, 
Alexa series exhibit greater photostability and 
enhanced fluorescence emission than those of the 
classical fluoroprobes such as fluorescein and 
rhodamine. These properties increase the sensitivity of 
the assays, facilitating the development of 
fluorescence-based techniques. With such powerful 
tools, coupled with the rapidly advancing 
complementary imaging technologies such as 
fluorescence correlation spectroscopy, one is therefore 
becoming able to investigate therapeutically important 
GPCRs and their molecular relationships with bioactive 
ligands at the single cell level and even at the single 
molecule level 11,12. This will open the way to study 
compartmentalization and structural organization of 
GPCRs in specialized microdomains of the cell plasma 
membrane. Thus this study provides simple and 
cheaper alternative for chromatographic evaluation of 
peptide hormones like vasopressin and octreotide 
using rhodamine B as a fluoroscent material. 
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